Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy without Choroidal Neovascular Membrane - a Pilot Study

To study intravitreal brolucizumab in the management of persistent macular fluid in chronic central serous chorioretinopathy (CSCR) without choroidal neovascular membrane (CNVM). Retrospective case series which included eyes with chronic CSCR with persistent macular fluid for ≥ 3 months without CNVM...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in ophthalmology 2024-11, Vol.39 (8), p.615-622
Main Authors: Ramamurthy, Srishti Raksheeth, Behera, Umesh Chandra, Narula, Ritesh, Sadda, SriniVas R, Narayanan, Raja
Format: Article
Language:English
Subjects:
Adult
Angiogenesis Inhibitors - administration & dosage
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - therapeutic use
Central Serous Chorioretinopathy - diagnosis
Central Serous Chorioretinopathy - drug therapy
Choroidal Neovascularization - diagnosis
Choroidal Neovascularization - drug therapy
Chronic Disease
Female
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Intravitreal Injections
Male
Middle Aged
Pilot Projects
Retrospective Studies
Subretinal Fluid
Tomography, Optical Coherence
Visual Acuity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To study intravitreal brolucizumab in the management of persistent macular fluid in chronic central serous chorioretinopathy (CSCR) without choroidal neovascular membrane (CNVM). Retrospective case series which included eyes with chronic CSCR with persistent macular fluid for ≥ 3 months without CNVM. Intravitreal brolucizumab was administered in all eyes. Primary outcome measure was the resolution of intraretinal (IRF) and/or subretinal fluid (SRF) on OCT. Five eyes (four patients) with chronic CSCR were included. All eyes showed complete resolution of SRF 1 month following injection. Minimal residual IRF was present in two eyes. Best corrected visual acuity (BCVA) was stable in three eyes, and two eyes showed improvement. Central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) showed reduction. Intravitreal brolucizumab is effective in the rapid reduction of persistent macular fluid in chronic CSCR without CNVM. Long-term follow-up data are required to study recurrence and adverse effect profile.
ISSN:0882-0538
1744-5205
1744-5205
DOI:10.1080/08820538.2024.2308808